Association of Beta-Blockers with Survival on Patients Presenting with ACS Treated with PCI: A Propensity Score Analysis from the BleeMACS Registry
Journal
American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
Date Issued
2018-08
Author(s)
D'Ascenzo, Fabrizio
Celentani, Dario
Brustio, Alessandro
Grosso, Alberto
Raposeiras-Roubín, Sergio
Abu-Assi, Emad
Henriques, Jose Paulo Simao
Saucedo, Jorge
González-Juanatey, José Ramón
Wilton, Stephen B
Kikkert, Wouter J
Nuñez-Gil, Iván
Ariza-Sole, Albert
Song, Xiantao
Alexopoulos, Dimitrios
Liebetrau, Christoph
Kawaji, Tetsuma
Huczek, Zenon
Nie, Shao-Ping
Fujii, Toshiharu
Correia, Luis
Kawashiri, Masa-Aki
García-Acuña, José María
Southern, Danielle
Alfonso, Emilio
Terol, Belén
Garay, Alberto
Zhang, Dongfeng
Chen, Yalei
Xanthopoulou, Ioanna
Osman, Neriman
Möllmann, Helge
Shiomi, Hiroki
Kowara, Michal
Filipiak, Krzysztof
Wang, Xiao
Yan, Yan
Fan, Jing-Yao
Ikari, Yuji
Nakahayshi, Takuya
Sakata, Kenji
Yamagishi, Masakazu
Moretti, Claudio
D'Amico, Maurizio
Gaita, Fiorenzo
DOI
10.1007/s40256-018-0273-4
Abstract
The aim was to evaluate prognostic value of beta-blocker (BB) administration in acute coronary syndromes (ACS) patients in the percutaneous coronary intervention (PCI) era.
